ArticleMicrobial genomics2023
Genomic analysis of the initial dissemination of carbapenem-resistant
Article in Microbial genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811727 (CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Global perspectives on Klebsiella epidemiology and biology: conference report on the KLEBS 2024 symposium.npj antimicrobials and resistance · 2026Article
- Article
- Systematic review on genomic insights into antimicrobial resistance in ESKAPE pathogens.African journal of laboratory medicine · 2026Review
- Genomic surveillance reveals different transmission patterns between third-generation cephalosporin and carbapenem resistance in Klebsiella pneumoniae in the Comunidad Valenciana (Spain), 2018-2020.Antimicrobial resistance and infection control · 2025Article
- Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients withFrontiers in pharmacology · 2025Article
- Whole-genome sequencing of Klebsiella pneumoniae MDR circulating in a pediatric hospital setting: a comprehensive genome analysis of isolates from Guayaquil, Ecuador.BMC genomics · 2024Article
- Predominance of OXA-48 carbapenemase-producingBiomolecules & biomedicine · 2024Article
- Identification of a novel CG307 sub-clade in third-generation-cephalosporin-resistantMicrobial genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.